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Regine Audran7, Elizabeth F. Wallin8, Said A. Jongo2, Kassim Kamaka2, Martin Zand4, Francois Spertini7, Claudia Daubenberger9,10, Anne E. Corcoran1,
and Michelle A. Linterman1
The generation of protective humoral immunity after vaccination relies on the productive interaction between antigen-
specific B cells and T follicular helper (Tfh) cells. Despite the central role of Tfh cells in vaccine responses, there is currently no
validated way to enhance their differentiation in humans. From paired human lymph node and blood samples, we identify a
population of circulating Tfh cells that are transcriptionally and clonally similar to germinal center Tfh cells. In a clinical trial
of vaccine formulations, circulating Tfh cells were expanded in Tanzanian volunteers when an experimental malaria vaccine was
adjuvanted in GLA-SE but not when formulated in Alum. The GLA-SE–formulated peptide was associated with an increase in
the extrafollicular antibody response, long-lived antibody production, and the emergence of public TCRβ clonotypes in
circulating Tfh cells. We demonstrate that altering vaccine adjuvants is a rational approach for enhancing Tfh cells in humans,
thereby supporting the long-lived humoral immunity that is required for effective vaccines.
Introduction
Vaccination is one of the most powerful interventions for re-
ducing the disability and death caused by infectious disease
worldwide (Andre et al., 2008). Despite its success, there are still
numerous pathogens that are not controlled by current vacci-
nation strategies, including HIV and Plasmodium spp., the para-
sites that cause malaria (Burton et al., 2012; Delany et al., 2014).
The majority of effective vaccines work by stimulating the
production of antibodies that bind the surface of the pathogen to
either block the pathogen’s ability to establish an infection or
recruit and stimulate other immune cells, resulting in the
pathogen’s destruction. Antibody production after vaccination
can occur via two cellular pathways, which although separated
in time and anatomical space, are both induced after vaccination
with a protein antigen. The first wave of antibody production
comes from the extrafollicular plasmablast response, in which
short-lived antibody-secreting cells (ASCs) produce immuno-
globulin for a few days (MacLennan et al., 2003). The second
wave of ASCs comes from the germinal center (GC) response.
The GC is a specialized microenvironment that forms in sec-
ondary lymphoid tissues after immunization, where antigen-
activated B cells clonally expand within the B cell follicle
and undergo somatic hypermutation (SHM) of their
immunoglobulin loci. The process of SHM, followed by the
affinity-based selection of GC B cells, results in the emergence
of long-lived, high-affinity, antibody-secreting plasma cells and
memory B cells that are able to provide protection against
subsequent infection (Vinuesa et al., 2016). The GC response is
absolutely dependent on a specialized subset of CD4+ T cells, T
follicular helper (Tfh) cells, which provide growth and differ-
entiation signals to GC B cells. Tfh cells mediate the positive
selection of B cell clones in the GC and thereby determine
which B cells exit the GC as plasma cells or memory B cells
(Vinuesa et al., 2016). Because Tfh cells are key determinants of
the long-lived humoral immunity that arises from the GC, they
represent an exciting therapeutic target through which vaccine
strategies could be improved (Linterman and Hill, 2016). This is
particularly pertinent for malaria vaccine development, as
clinical trials indicate that the development of long-lived anti-
body responses, in particular for the preerythrocytic and blood
stages of infection, are essential for sustained protective im-
munity (Cockburn and Seder, 2018).
Adjuvants are an attractive way to improve vaccine re-
sponses in humans. This is reflected in the licensing of four new
adjuvants in recent years: MF59, AS01, AS02, and AS04 (Garçon
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and Di Pasquale, 2017). Nevertheless, the number of adjuvants
that are in use in current vaccines is still very limited, largely
unchanged since the 1940s, as is our understanding of how ad-
juvants boost a specific cellular immune response in humans.
While studies in animals indicate that adjuvants are a valid way
to boost the GC and Tfh cell response (Aloulou et al., 2016;
Desbien et al., 2016; Liang et al., 2017), translational work is
needed to determine if using novel adjuvants can boost these
responses in humans. Despite Tfh cells being central for long-
term humoral immunity, most human vaccine studies have not
included these cells in their analysis, rather focusing on
cytokine-producing CD4+ T cells (Coler et al., 2015), an approach
that does not accurately capture vaccine-reactive Tfh cells (Dan
et al., 2016). The tendency to omit the analysis of Tfh cells in
human vaccination studies may be due to difficulty in studying
these cellular responses. Tfh cells are located in secondary
lymphoid tissue, which is not easily sampled during vaccine
trials. To circumvent this issue, a population of circulating Tfh-
like (cTfh) cells that are found in the blood and phenotypically
and functionally resemble lymphoid tissue Tfh cells can be used
as a biomarker of ongoing Tfh cell responses (Simpson et al.,
2010; Chevalier et al., 2011; Morita et al., 2011; Bentebibel et al.,
2013; He et al., 2013; Locci et al., 2013). Here, we have used a
seasonal influenza vaccination study and analyses of CXCR5+
Tfh cell populations from the blood and LNs of human donors to
refine our understanding of cTfh cells as circulating biomarkers
of bona fide Tfh cells resident in secondary lymphoid tissues.We
then applied this knowledge to determine whether the combi-
nation adjuvant glucopyranosyl lipid adjuvant-stable emulsion
(GLA-SE; developed by the Infectious Disease Research Institute,
Seattle, WA) can augment cTfh cell responses. In a phase Ib
malaria vaccine trial in Tanzania, we show that a GLA-
SE–formulated vaccine is superior to one formulated with Al-
hydrogel (Alum). GLA-SE induced a greater extrafollicular
antibody response and increased the formation of cTfh cells,
including cTfh cells with transcriptional similarity and a clonal
relatedness to LN GC-Tfh cells. While the different adjuvants did
not induce differential gene expression profiles in cTfh cells,
multiple GLA-SE–vaccinated individuals had cTfh cells ex-
pressing public TCRβ clonotypes, indicating that GLA-SE may
support the recruitment of T cells bearing specific TCRs to the
Tfh cell compartment or promote their subsequent expansion.
This demonstrates that experimental vaccine adjuvants offer a
viable strategy to enhance Tfh responses and long-lived humoral
immunity in humans.
Results
cTfh cells clonally expand after vaccination
The aim of our study was to determine whether the adjuvant
GLA-SE promotes a cTfh cell response in humans. The location
of the GC response, within secondary lymphoid tissues, is one of
the major barriers to understanding how different vaccines, and
their adjuvants, affect GC biology in humans. For this reason,
circulating cells that can act as biomarkers of the GC response
are an area of intense interest. In particular, it is well established
that there is a population of blood CXCR5+CD4+ cells that
expands after vaccination (Bentebibel et al., 2013; He et al., 2013;
Locci et al., 2013) and that these cTfh cells phenotypically and
functionally resemble lymphoid tissue Tfh cells (Linterman and
Hill, 2016). There is considerable heterogeneity in the circulat-
ing CXCR5+CD4+ T cell compartment, with multiple subsets
described within this population (Schmitt et al., 2014). Because
of this heterogeneity, we first sought to identify the subpopu-
lation of CXCR5+CD4+ T cells that were activated by vaccination
to enable us to refine our analyses. Inducible costimulator
(ICOS) and CD38 are receptors expressed on the cell surface of
tonsillar Tfh cells but not CD45RA− non-Tfh cells (Fig. S1, A–D).
The frequency of ICOS+CD38+ tonsillar Tfh cells correlates with
the percentage of GC B cells (Fig. S1 E), suggesting that cTfh cells
expressing these markers may represent a circulating surrogate
of activated lymphoid tissue Tfh cells. We first tested expression
of these cell-surface receptors after seasonal influenza vaccina-
tion, a routine nonadjuvanted inoculation in which cTfh cell
expansion has been well described (Bentebibel et al., 2013) and
in which expression of ICOS and CD38 has been reported
on cTfh cells (Bentebibel et al., 2013; Herati et al., 2017;
Koutsakos et al., 2018). We observed an expansion of
ICOS+CD38+CXCR5+PD-1+ cTfh cells in healthy UK volunteers
(n = 41) 7 d after vaccination (Fig. 1, A and B), the peak of the
cTfh cell response (Bentebibel et al., 2013; Carr et al., 2016).
This expansion of ICOS+CD38+CXCR5+PD-1+ cTfh cells corre-
lated positively with the increase in influenza-specific anti-
bodies 7 and 42 d after vaccination (Fig. 1, C and D; and Fig. S1, F
and G). In addition, using HLA-DR tetramers in a subset of the
volunteers with the appropriate HLA genotype (Yang et al.,
2013), we were able to identify hemagglutinin (HA)-specific
ICOS+CD38+CXCR5+PD-1+ cTfh cells 7 d after vaccination (Fig.
S2, A–C). These data indicate that ICOS+CD38+CXCR5+PD-1+
cTfh cells could be a good biomarker of lymphoid tissue Tfh
cells that support humoral immunity.
To gain insight into how vaccines qualitatively alter Tfh
cell responses, we performed RNA sequencing of 200
ICOS+CD38+CXCR5+PD-1+ cTfh cells immediately before and
7 d after influenza vaccination in four individuals. Differential
gene expression analysis of these cTfh cells indicated up-
regulation of CXCR3 and down-regulation of CCR6 tran-
scripts in cTfh cells isolated 7 d after vaccination (Fig. 1 E).
This difference in mRNA was also reflected at the protein
level, with the proportion of CXCR3+ cTfh cells increasing
after influenza vaccination and a reciprocal decrease in CCR6+
cTfh cells (Fig. 1 F). This is consistent with previous work
demonstrating that influenza vaccination results in a Th1-
skewing of the Tfh cell population (Bentebibel et al., 2013).
Transcriptomic analysis also enabled an assessment of the
TCR usage within cTfh cells. Assessment of the nucleotide
sequence encoded by the CDR3 region of the TCRβ chain re-
vealed ∼160 TCRβ clonotypes per person that were unique at
the amino acid level before vaccination (Fig. 1 G), a number
that is consistent with the 200 cells sequenced. After vacci-
nation, the number of unique TCRβ clonotypes identified per
person was reduced (Fig. 1 G), consistent with clonal expan-
sion of cTfh after influenza vaccination as previously de-
scribed (Herati et al., 2017). This reduction in diversity was
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driven by the expansion of a few clones: before vaccination,
most TCRβ clonotypes represented <2% of the total CDR3
reads, whereas 7 d after vaccination, 6–10 unique CDR3 se-
quences per individual were present at higher frequencies
(Fig. 1 H). This indicates that the cTfh cell response to influ-
enza vaccination is dominated by the expansion of a small
number of T cell clones. In summary, the combination of flow
cytometric analysis and RNA sequencing identifies the
ICOS+CD38+CXCR5+PD-1+ cTfh cell population as a biomarker
of ongoing Tfh cell responses and provides a quantitative and
qualitative way to assess the biology of these cells during
human vaccine trials.
Figure 1. ICOS and CD38 mark cTfh cells
following seasonal influenza vaccination.
(A and B) Flow cytometric contour plots (A)
and quantification (B) of the frequency
of CD38+ICOS+CXCR5+PD-1+ cells among
CD45RA−CD4+CD3+ cells in the peripheral blood
of healthy UK donors at days 0 and 7 relative to
seasonal influenza vaccination; n = 41. (B) Each
symbol represents a volunteer; an individual
donor is connected by a line at the two time
points; n = 41. P < 0.0001; the P value was
generated with a Wilcoxon signed-rank test.
(C and D) Correlation of the frequency of
CD38+ICOS+CXCR5+PD-1+ cTfh cells 7 d after
vaccination with the change in antibody titer of
anti-Cal09 IgG (C, an influenza A HA, P = 5.3 ×
10−7, Rho = 0.75) and anti-Bris08 IgG (D, an
influenza B HA, P = 5.5 × 10−7, Rho = 0.79) 7 d
after vaccination. Statistical analysis by Spear-
man’s correlation (Rho = coefficient); n = 41.
(E) Scatterplot of whole transcriptome RNA-
sequencing data comparing the expression of
all genes expressed in CD38+ICOS+CXCR5+PD-
1+ cells before and 7 d following seasonal
influenza vaccination; n = 4. Differentially ex-
pressed genes (DESeq2) are indicated in blue.
(F) Flow cytometric contour plots of CXCR3 and
CCR6 expression on ICOS+CXCR5+PD-1+ Tfh
cells at the indicated time points relative to
vaccination, a representative example of 36
individuals. (G) The number of unique TCRβ
CDR3 amino acid sequences identified in RNA-
sequencing libraries from CD38+ICOS+CXCR5+PD-
1+ cTfh cells from four volunteers were analyzed at
days 0 and 7 relative to vaccination; n = 4. P =
0.0017; the P value was generated with a paired
Student’s t test. (H) Quantification of the per-
centage of total TCRβ CDR3 reads per unique
clone: each symbol represents a unique CDR3
amino acid sequence. The dotted line indicates a
frequency of 2%. In H, each letter on the x axis
corresponds to a different volunteer. Data are from
one seasonal influenza vaccination cohort.
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A GLA-SE–formulated vaccine promotes long-lasting IgG
responses in humans
The P27A antigen is a 104–amino acid peptide of the PFF0165c
protein from the malaria-causing protozoan Plasmodium falci-
parum. Because seroreactivity to P27A is high in populations
naturally exposed to malaria, and anti-P27A IgG can inhibit
asexual blood stage parasite growth in vitro (Olugbile et al.,
2009), P27A offers a rational vaccine target to prevent malaria
disease. In a phase Ib clinical trial with adults from Tanzania, the
P27A peptide (50 µg) was formulated with one of two adjuvants:
the widely used Alum (Alhydrogel) or the experimental adjuvant
GLA-SE (5 µg), a synthetic TLR4 agonist, enabling side-by-side
comparison of vaccine-induced immunity (Steiner-Monard
et al., 2019). All participants were malaria preexposed but had
no clinical malaria episode recorded in the past 5 yr. The vol-
unteers were given three doses of either vaccine, each 1 mo
apart, with blood samples taken for serology at multiple time
points over a 34-wk follow-up period (Steiner-Monard et al.,
2019; sampling schedule in Fig. 2 A). In each participant, we
detected low levels of anti-P27A antibodies before vaccination,
which was not different between adjuvant groups, indicating
that responses to the P27A vaccination involve reactivation of
P27A-specific memory lymphocytes (Fig. 2 B). It is important to
study vaccine responses in cohorts with preexposure, as only a
vaccine that successfully induces protective immunity in in-
dividuals living in malaria-endemic regions will limit malarial
disease burden. Individuals with preexposure have been shown
to mount poorer humoral responses in experimental malaria
vaccine trials than unexposed individuals, including to the P27A
peptide (Steiner-Monard et al., 2019). After vaccination, P27A
induced a higher anti-P27A IgG response when formulated in
GLA-SE compared with Alum from day 63 through day 238
(Fig. 2 B). In contrast to Alum, a significant further increase in
serum anti-P27A IgG titers was observed 28 d after the third
vaccination in the GLA-SE group (Fig. 2 C). This is the peak of
the antibody response in this study, and a time when vaccine-
specific antibodies are most likely derived from both extra-
follicular and GC-derived ASCs. To determine whether the ad-
juvant has an impact on the longevity of the antibody response,
we calculated the proportion of peak (day 84, 28 d after the final
vaccination) anti-P27A IgG antibodies that remain at later time
points (Fig. 2 D). 6 mo after the final vaccination, individuals
vaccinated with GLA-SE–formulated antigen had ∼25% of peak
antibody titers remaining compared with ∼18% in the Alum-
treated group (Fig. 2 E). There was no significant difference in
the subclass of the IgG produced, with IgG1 dominating the re-
sponse in both groups (Fig. 2 F). Together, these indicate that the
adjuvant GLA-SE increases both the magnitude and longevity of
the anti-P27A antibody response compared with Alum.
GLA-SE drives higher frequencies of cTfh cells compared with
Alum
Tfh cells regulate GC size and are essential for the emergence of
long-lived plasma cells and memory B cells from the GC;
therefore, boosting Tfh cell number is a rational strategy to
enhance vaccine responses (Linterman and Hill, 2016). In this
clinical trial, only volunteers receiving the vaccine containing
GLA-SE had an expansion of the ICOS+CD38+CXCR5+PD-1+ cTfh
cell population 7 d after the third vaccination (Fig. 3, A–C), and
the increase in cTfh cell frequency correlated positively with an
increase in anti-P27A IgG at peak response (Fig. 3 D). This
demonstrates that altering the vaccine adjuvant is a rational
approach to enhance the magnitude of the cTfh cell response in
humans. These data show that GLA-SE can provoke a robust
boost of humoral immunity even in the context of high preex-
isting antibody titers induced by the previous two P27A in-
oculations. This finding is critical in cases where preexisting
natural antigen exposuremay have a negative impact on vaccine
responses, such as in malaria-endemic regions like Tanzania.
Public TCRβ clonotypes identified in cTfh cells from
GLA-SE–inoculated individuals
As GLA-SE quantitatively altered the cTfh cell response in hu-
mans, we wanted to determine if it also has a different quali-
tative effect compared with Alum on this cell population.
Previous studies have shown that CXCR5+CD45RA−CD4+ cTfh
cells have B cell helper capacity in vitro (Simpson et al., 2010;
Chevalier et al., 2011; Morita et al., 2011; Bentebibel et al., 2013;
He et al., 2013; Locci et al., 2013). In this study, <500 ICOS+CD38+
cTfh cells were isolated per person, meaning coculture studies to
address the functional capacity ex vivo could not be pursued, but
low-cell-number RNA sequencing was still achievable. As es-
tablished in our UK influenza vaccination study (Fig. 1), we
performed total RNA-sequencing on 150–200 ICOS+CD38+ cTfh
cells per person before vaccination (day 0), and 7 (day 63) and 28
(day 84) d after the third vaccination. There was no significant
alteration in the cTfh cell transcriptome between adjuvant
groups (Alum, n = 7; GLA-SE, n = 8) 7 d after the third vacci-
nation (Fig. 3 E) or at the other time points analyzed (data not
shown). This suggests that while the GLA-SE–formulated pep-
tide increases the magnitude of the cTfh cell response, it is not
likely to alter cTfh cell function when compared with Alum.
Consistent with this, there was no difference in the mRNA ex-
pression of the key cTfh effector molecules CD40LG or IL21 be-
tween the two volunteer groups (Fig. 3, F and G). In contrast to
what was observed in the UK unadjuvanted influenza vaccina-
tion cohort, there was no significant change in the CXCR3 or
CCR6 transcripts (Fig. 3, H and I), indicating that the Th1/2/17
phenotype of these cTfh cells is not skewed by either adjuvant.
This observation is consistent with the similar distribution of
P27A-specific IgG subclasses found after vaccination (Fig. 2 F).
To determine whether adjuvant choice had an effect on the
clonality of the cTfh response, we examined TCRβ sequences in
our RNA-sequencing dataset of samples from days 0, 63, and 84.
There was no evidence of clonal expansion in either adjuvant
group (Fig. S3), but common clones were identified between
samples. Within the Alum group, we identified 10 TCRβ clono-
type sequences that were shared between samples (five distinct
clones, each present in two separate samples); however, with
one exception, these were only shared within individuals at
different time points (Fig. 4 A). In the GLA-SE–vaccinated group,
of the nine distinct TCRβ clones that were common between two
different samples, six were public TCRβ clonotypes, shared be-
tween five different individuals (Fig. 4 B). Strikingly, these
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shared TCRβ clonotypes were not commonly detected in samples
frombaseline and day 84 butwere identified at the peak of the cTfh
response (day 63) in five of eight GLA-SE–vaccinated individuals
(Fig. 4, C and D). These data indicate that GLA-SE may either
promote the recruitment or selective expansion of T cells ex-
pressing shared TCRβ clonotypes into the cTfh cell compartment.
GLA-SE–formulated vaccines stimulate the extrafollicular ASC
response
Because GLA-SE promoted the expansion of cTfh cells, we
wanted to determine whether this adjuvant also has an impact
on the B cell response after vaccination. To this end, we assessed
the number and the repertoire of peripheral blood ASCs.
Despite the increase in P27A antibody titers (Fig. 2, B and C),
there was not an increase in the frequency of circulating
CD38+CD20−CD19+ ASC 7 d after the third vaccination (day 63) in
either group relative to baseline (Fig. 5, A and B). This may be
because it is difficult to detect numerical changes in blood ASCs
in Tanzanian individuals due to higher baseline frequencies
than in age-matched samples from our UK cohort (Fig. S4 A).
Alternatively, this may be because 7 d after the third vaccination
(day 63) is not the peak of the circulating ASC response in this
Figure 2. The adjuvant GLA-SE enhances antibody production but not early ASC expansion. (A) Vaccination and venepuncture schedule for the clinical
trial. (B) Anti-P27A IgG antibody titers in volunteers vaccinated with 50 µg P27A peptide in either Alum (black) or GLA-SE (white); error bars represent the 95%
confidence interval. Day 0, NS; day 28, NS; day 56, NS; day 84, P = 0.03; day 82, P = 0.015; day 238, P = 0.007. The P values were calculated using a two-way
ANOVA with Sidak’s multiple-comparisons test; n = 8/group. Log10 anti-P27A titers are shown. (C) Change in anti-P27A IgG antibody titer 28 d after the third
vaccination (d84); n = 8/group; P = 0.043. (D and E) Anti-P27A IgG titer normalized to the peak of the antibody response (d84) in volunteers vaccinated with 50
µg P27A peptide in either Alum (black) or GLA-SE (white); n = 8/group. In D, error bars represent the 95% confidence interval; P = 0.02 (D); P = 0.01 (E). The P
values were calculated using a two-way ANOVA. (F) Pie chart of the total anti-P27A IgG pool at day 84 divided by immunoglobulin isotype; n = 8/group. IgG1, P =
0.52; IgG2, P = 0.51; IgG3, P = 0.96; IgG4, P = 0.11. In C and E, the height of the bar represents the median, and each symbol represents one individual; those who
received Alum are shown in black, and those who received GLA-SE are in white. In C, E, and F, P values were calculated using a Mann-Whitney U test. Data are
from one clinical trial.
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vaccine trial. An alternative strategy to understand the detailed
nature of B cell responses in humans after vaccination is to assess
the clonality and mutation rate in ASCs. To investigate the
characteristics of vaccine-induced ASCs, we performed V(D)J
RNA sequencing of immunoglobulin heavy chain IgG (IgHG)
repertoires in blood ASCs from all individuals 7 d after the third
vaccination (day 63). The analysis revealed that individuals with
high titer antibody responses (defined as anti-P27A IgG >500
arbitrary units [AU] at day 84) had oligoclonal expansion of ASC
clones 7 d after the third vaccination (Fig. 5, C and D; and Fig. S4
B). Strikingly, these individuals showed an enrichment of IgHG
clonotypes with fewer somatic mutations in their IgG heavy
chain variable region (FR1–FR3 regions), compared with the
blood sample obtained before vaccination (Fig. 5, E–H). This
indicates that high-titer responders have more circulating ASCs
derived from the extrafollicular antibody response than low
responders. This decreased frequency of mutations occurred
more frequently in GLA-SE–vaccinated individuals than in those
that received the Alum-formulated P27A peptide (Fig. 5 H),
suggesting that GLA-SE stimulates extrafollicular ASC responses
more efficiently than Alum. This observation is consistent with a
murine study showing that GLA-SE stimulates a greater number
of antigen-specific plasmablasts in the draining LN after im-
munization than anAlum-formulated vaccination (Desbien et al.,
2016). It is important to note that this occurs in parallel with an
enhancement of the GC response, demonstrating that both
Figure 3. A GLA-SE adjuvanted vaccine pro-
motes cTfh expansion. (A and B) Flow cyto-
metric contour plots of (A) PD-1 and CXCR5
on total CD45RA−CD4+CD3+ cells and (B) ICOS
and CD38 on the population gated in A on
peripheral blood cells from individuals 7 d after
the third P27A vaccination. Alum group, n = 7;
GLA-SE group, n = 8. (C) Fold change of
CD38+ICOS+CXCR5+PD-1+ cTfh cells 7 d after
the third P27A vaccination (frequency of cTfh
cells at day 63/baseline). Alum group, n = 7;
GLA-SE, group n = 8. P = 0.027. The P value is
from an unpaired Student’s t test. (D) Correla-
tion of anti-P27A IgG antibody titer 28 d after
the third vaccination against fold change in
CD38+ICOS+CXCR5+PD-1+ cTfh cells 7 d after
the third vaccination. Rho = 0.73; P = 0.003
by Spearman’s correlation (Rho = coefficient);
n = 15. (E) Scatterplot of RNA-sequencing
data comparing all genes expressed in
CD38+ICOS+CXCR5+PD-1+ cTfh cells 7 d after
the third P27A vaccination in either Alum- (x
axis) or GLA-SE– (y axis) vaccinated groups.
Alum group, n = 7; GLA-SE group, n = 8. (F–I)
Bar plots showing log-normalized reads from
RNA-sequencing data of CD40LG. P = 0.593 (F),
IL21 P = 0.846 (G), CXCR3 P = 0.606 (H), and
CCR6 P = 0.977 (I) for transcripts in ICOS in
CD38+ICOS+CXCR5+PD-1+ cTfh cells 7 d after the
third P27A vaccination; Alum group, n = 7; GLA-
SE group, n = 8. P values were calculated using
DESeq2 with a false discovery rate correction.
Each symbol represents one individual; those
who received Alum are shown in black, and
those who received GLA-SE are in white. Data
are from one clinical trial.
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responses can be simultaneously enhanced by GLA-SE in mice
and that this adjuvant does not skew the B cell response in favor
of one pathway over the other (Desbien et al., 2016; Olafsdottir
et al., 2016).
Transcriptional analysis identifies circulating counterparts of
GC-Tfh cells
In both mice and humans, Tfh cells play essential roles within
the GC (GC-Tfh) and outside the B cell follicle supporting the
extrafollicular antibody response (McHeyzer-Williams et al.,
2009; Bentebibel et al., 2011; Lee et al., 2011). Our results indicate
that GLA-SE is able to promote both cTfh cell and extrafollicular
antibody responses, prompting the hypothesis that using
ICOS+CD38+CXCR5+PD-1+ cTfh cells as a biomarker of Tfh cells,
as in our study, does not discriminate between GC-Tfh and ex-
trafollicular Tfh cells, which would both be expected to form
after vaccination to support their respective B cell responses.
Recent studies suggest that cTfh cells with the highest expres-
sion of PD-1 represent a highly activated cTfh cell population
(Schmitt et al., 2014; Heit et al., 2017), and their similar phe-
notype to LN GC-Tfh suggests that CXCR5+PD-1+++ cTfh cells
may represent a distinct biomarker of GC-Tfh cells. To test this
hypothesis, four different CD4+CD45RA− T cell subsets were
sorted based on their expression of CXCR5 and PD-1 (gating
shown in Fig. 6 A), including bona fide LN CXCR5+PD-1+++Bcl-6+
Tfh cells (Fig. 6 B), from paired human blood and iliac LN
samples from six individuals, and their transcriptomes were
sequenced as described above. Hierarchical clustering of the
most variable genes shows that CD4+CD45RA− T cell subsets
from blood clusters with their corresponding subset from LNs
expressing the same cell surface phenotype (Fig. 6 C). Principal
component (PC) analysis shows that majority of variation in the
data is driven by the cell phenotype (PC1, 30%) while the second
contributor to variation (PC2, 11%) is tissue origin (Fig. 6 D).
Together, this strongly suggests that the CXCR5+PD-1+++ cTfh
population most closely resembles the LN resident CXCR5+PD-
1+++Bcl6+ GC-Tfh cell type. To further determine to what extent
the transcriptome of the cTfh cells overlaps with that of the GC-
Tfh population (LN 4, Fig. 6 A), we first generated a list of 254
genes that were differentially expressed in GC-Tfh (LN 4)
compared with the three other LN populations (LN 1, 2, 3), then
used this gene signature to compare with the four different
blood CD4+CD45RA− populations (Fig. 6 E). The CXCR5+PD-1+++
cTfh population clustered most closely with the LN GC-Tfh cell
population, with a number of gene modules showing the same
expression pattern (Fig. 6 E); for example, the canonical Tfh
genes ASCL2, IL21, and ICOS show the same expression patterns
in both LN and circulating CXCR5+PD-1+++ cells (Fig. 6 F). No-
tably, IL7R expression is low in both LN and circulating
CXCR5+PD-1+++ cells (Fig. 6 F), consistent with a GC-Tfh
Figure 4. A GLA-SE adjuvanted vaccine elicits common TCRβ clonotype
usage. (A and B) Circos plots of shared TCRβ CDR3 amino acid sequences in
CD38+ICOS+CXCR5+PD-1+ cTfh cells from donors who received the P27A
vaccine in (A) Alum or (B) GLA-SE. Alum group, n = 7; GLA-SE group, n = 8.
Each line represents a TCRβ CDR3 amino acid sequence shared with another
sample, and a different color was used for each participant. (C)Quantification
of the number of shared CD38+ICOS+CXCR5+PD-1+ cTfh TCRβ CDR3 amino
acid sequences per donor either before vaccination (P = 0.5536; left, sharing
between day 0 samples) or 7 d after the third vaccination (P = 0.0089; right,
sharing between day 63 samples). Alum group, n = 7; GLA-SE group, n = 8.
(D) TCRβ gene usage and CDR3 amino acid sequence of the TCRβ CDR3
clonotypes shared between GLA-SE–vaccinated individuals at day 63. P val-
ues were calculated using a two-tailed unpaired Student’s t test. Each symbol
represents one individual; those who received Alum are shown in black, and
those who received GLA-SE are in white. Data are from one clinical trial.
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Figure 5. V(D)J sequencing shows low BCR mutation frequency in individuals with high titer antibody responses. (A and B) Flow cytometric contour
plots (A) and quantitation (B) of peripheral blood CD38+CD20− cells of total CD19+ cells 7 d after the third vaccination (day 63). Alum group, n = 7; GLA-SE
group, n = 8. P = 0.21. In B, the height of the bar represents the median. P values were calculated using a Mann-Whitney U test, and each symbol represents one
individual: those who received Alum are shown in black, and those who received GLA-SE are in white. (C and D) Pie charts of the proportions of the 100 most
abundant IgHG clonotypes in CD38+CD20−CD19+ ASCs from C, a representative individual whose anti-P27A IgG does not increase >500 AU after the third
vaccination (day 84–day 0), and D, a representative individual who has a high anti-P27A titer after the third vaccination (day 84 to day 0). Each segment of the
pie chart represents a unique BCR clonotype. (E and F) Line graphs of the number of mutations in the V region of each clonotype (FR1–FR3, excluding CDR3,
binned into five mutation bins) for the individuals shown in A and B, respectively, at the indicated time points relative to vaccination. (G and H) The percentage
of IgHG clonotypes with ≤10 mutations in low (n = 4; P = 0.1692) and high antibody responders (n = 7; P = 0.0056; G) and in the different adjuvant groups, Alum
group n = 4, P = 0.1274; GLA-SE group n = 7, P = 0.0313 (H). In G and H, each individual is connected with a line between their day 0 and day 63 samples. The P
values were from a paired Student’s t test. Individual participants’ clonotype data for all other samples that passed sequencing quality control are included as
Fig. S4. Data are from one clinical trial.
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Figure 6. Transcriptional analysis identifies circulating counterparts of GC-Tfh cells. (A and B) Flow cytometric plots showing the gating strategy of the
four populations of CD4+CD3+CD45RA− cells sorted from iliac LNs (left) and peripheral blood (right) for RNA-sequencing and the expression of BCL6 protein in
these populations, with representative plots shown; n = 6 individuals. (C and D) Hierarchical clustering (C) and PC analysis (D) of the most highly variable
transcripts (standard deviation, >0.7) from RNA-sequencing data from four populations sorted in A from blood and LN samples. Three peripheral blood samples
from the blood population no. 4 were excluded from the analysis as they did not pass quality control. In D, each symbol represents one individual. (E) Su-
pervised analysis of the RNA-sequencing data from the four populations isolated from the blood using a gene signature for the LN GC-Tfh cells (LN 4); n = 254
genes. (F) Expression of IL7R, ASCL2, IL21, ICOS, and S1PR2 mRNA from RNA-sequencing data of the populations sorted in A; cell types are indicated by the
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phenotype (Bentebibel et al., 2011). However, there are differ-
ences between the LN and circulating populations, as exempli-
fied by low expression of S1PR1 on LN-GC-Tfh cells but high
expression on CXCR5+PD-1+++ cTfh cells (Fig. 6 F), consistent
with its role as a blood-localizing receptor on T cells. Analysis of
the TCRβ CDR3 sequences from the paired blood and LN cell
populations revealed that a high proportion of CDR3 sequences
were shared between CXCR5+PD-1+++ cTfh and GC-Tfh cells
(Fig. 6 G), consistent with a previous study that sequenced the
TCR of PD-1+ICOS+ cTfh cells (Heit et al., 2017). Combined, our
data demonstrate that CXCR5+PD-1+++ cTfh cells are clonally and
transcriptionally most closely related to GC-Tfh in secondary
lymphoid tissues; this shared ontology and antigen specificity
mean this cTfh population can be used as a surrogate for GC-
Tfh cells.
The expansion of CXCR5+PD-1+++ cTfh cells is enhanced in
GLA-SE–vaccinated participants
The direct comparison of paired blood and LN samples indicated
that CXCR5+PD-1+++ cTfh cells may be a circulating biomarker of
GC-Tfh cells. Next, we tested whether CXCR5+PD-1+++ cTfh ex-
pansion correlated more with vaccination-induced long-term
IgG responses measured after influenza and P27A vaccination,
as long-term antibody responses are GC derived. CXCR5+PD-1+++
cTfh cells expanded after seasonal influenza vaccination in our
UK cohort, confirming their responsiveness to immunization
(Fig. 7, A and B; Carr et al., 2016; Heit et al., 2017) and the
presence of HA-specific T cells within this population was
confirmed (Fig. S2, D and E). This expansion also correlates with
the increase in antibody titer 42 d after vaccination (Fig. 7 C). To
determine the effect that GLA-SE has on this population, we
reanalyzed our flow cytometry data from the P27A vaccine trial
with this alternate gating strategy. There was a significant ex-
pansion of CXCR5+PD-1+++ cTfh cells in the GLA-SE group but
not in those volunteers who received the Alum-formulated
peptide (Fig. 7 E). Importantly, the increase in CXCR5+PD-1+++
cTfh cells at day 63 correlated with long-term antibody titers
assessed on day 238 (Fig. 7 F), suggesting that this population
may promote the acquisition of long-term humoral immunity, a
property consistent with stimulating a GC response. These data,
together with murine research demonstrating GLA-SE promotes
GC B cell number in the draining LN (Desbien et al., 2016),
suggest that GLA-SE is a rational choice of adjuvant for en-
hancing the GC response and long-lasting humoral immunity in
humans.
Discussion
Adjuvants are currently the most tractable way of altering how
the human immune system responds to vaccination. The
majority of licensed vaccines provide protection against subse-
quent infection by generating long-lived antibody responses.
Therefore, adjuvants that enhance the magnitude of the GC re-
sponse are a logical approach to enhancing humoral immunity.
The size and quality of the GC response depend on the quantity
of Tfh cells that are induced by vaccination. While animal
studies clearly show that different adjuvants can enhance the
Tfh cell response (Aloulou et al., 2016; Desbien et al., 2016), these
findings need to be translated into human studies. Here, we
show that a next-generation adjuvant can be used to enhance the
magnitude of the Tfh cell response in humans. The GLA-SE
adjuvant increases both the ICOS+CD38+CXCR5+PD-1+ total cTfh
cell population and the GC-Tfh–like CXCR5+PD-1+++ cell popu-
lation after P27A vaccination, indicating that this adjuvant en-
hances the GC response. The analysis of the ASCs by V(D)J
sequencing showed that GLA-SE also enhances the extra-
follicular response. The data presented here are consistent with
a mouse immunization study showing that antigen formulated
with GLA-SE enhances Tfh cell numbers, the GC reaction, and
plasmablasts in secondary lymphoid tissues after immunization
(Desbien et al., 2016). Together, this demonstrates that GLA-SE
enhances the magnitude of the humoral immune response
rather than skewing it toward either the GC reaction or the
extrafollicular antibody response. The stimulation of both these
ASC sources in parallel maximizes the production of vaccine-
specific antibodies. This demonstrates that GLA-SE can be used
to make vaccines that potentiate Tfh cell and antibody responses
in humans.
Rapid antibody production after vaccination is supported by
the extrafollicular ASC response. During a primary response,
extrafollicular ASCs usually do not exhibit strong SHM in their
antibody variable (V) gene segments because they do not derive
from GCs. Importantly, our study was done on malaria-
preexposed volunteers who received three P27A vaccinations
at monthly intervals. Therefore, ASCs measured after the third
vaccination could have differentiated from memory B cells de-
rived either from a GC reaction after the first two P27A immu-
nizations or from a natural malaria infection. These memory
B cell–derived ASCs would be expected to have fewer somatic
mutations than GC-derived ASCs because memory B cells
emerge from the GC before long-lived plasma cells (Weisel et al.,
2016). Consistent with this, individuals with high titer antibody
responses 7 d after the third vaccination had mutations present
in the FR1–FR3 regions of the antibody V gene segments; how-
ever, the frequency of mutations was lower than ASCs at base-
line. This indicates these ASCs were likely of extrafollicular
origin and suggests that the precursors of these ASCs were
memory B cells that underwent low-level SHM during a GC
response to one of the previous vaccinations in the vaccine
trial. This FR1–FR3 region low-mutation signature was more
colors shown in A. RNA-sequencing data were standardized relative to a library size of 1 million reads, and then read counts were log2 transformed; a value of
−5 represents the limit of detection. P values were determined using ANOVA and the Tukey multiple-comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
(G) Quantification of the number of TCRβ CDR3 amino acid sequence clonotypes found in each blood cell population that are shared with the different LN
populations (for each cell type n = 6 donors, except blood population no. 4 where n = 3; shared numbers of clonotypes were converted to normalized
pseudocounts as described in Statistical analyses and Materials and methods). PBMC1, P = 0.055; PBMC2, P = 0.59; PBMC3, P = 0.0062; PBMC4, P = 0.029. The
P values were determined using Kruskal-Willis tests. Data are from six individuals in one experiment.
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prevalent in individuals receiving the GLA-SE–formulated vac-
cine and is consistent with the number of mutations reported in
memory B cells (DeWitt et al., 2016) and memory B cell–derived
ASCs after seasonal influenza vaccination in humans (Ellebedy
et al., 2016). Studies in mice have shown that GLA-SE augments
the formation of early ASCs in the draining LN (Desbien et al.,
2016; Olafsdottir et al., 2016), and our findings indicate that in
humans GLA-SE can also enhance the recruitment of memory
B cells into an extrafollicular ASC response.
The generation of humoral immunity after vaccination oc-
curs in secondary lymphoid tissues, which has hindered our
ability to study detailed cellular vaccine responses in humans.
Since the first descriptions of the expansion of a population of
cTfh cells in the blood in patients with autoimmunity (Simpson
et al., 2010) and subsequently after vaccination (Bentebibel
et al., 2013; He et al., 2013), there has been growing interest in
using cTfh cells as a biomarker of the GC response in humans
(Linterman and Hill, 2016). A single unifying definition of what
a Tfh cell is or a description of how they should be identified has
yet to be precisely demarcated. It has been proposed that Tfh
cells are defined by their capacity to provide help to B cells, and
those that do so in the context of a GC reaction are described as
GC-Tfh cells, thereby subsetting the total Tfh cell population by
the site at which it functions (McHeyzer-Williams et al., 2009;
Figure 7. The expansion of CXCR5+PD-1+++ cTfh
cells is enhanced by a GLA-SE adjuvanted vaccine.
(A and B) Flow cytometric contour plots (A) and quantifi-
cation (B) of the frequency of CXCR5+PD-1+++ cells among
CD45RA−CD4+CD3+ cells in the peripheral blood of healthy
UK donors at days 0 and 7 relative to seasonal influenza
vaccination; n = 41; in B, each symbol represents a volun-
teer, and an individual donor is connected by a line at the
two time points; n = 41. P < 0.0001. The P value was cal-
culated using Wilcoxon signed-rank test. (C) Correlation of
the frequency of CXCR5+PD-1+++ cTfh cells 42 d after vac-
cination with the change in antibody titer of anti-Cal09 IgG
(an influenza A HA); Rho = 0.6; P = 0.0001 using Spear-
man’s correlation (Rho = correlation coefficient). (D) Flow
cytometric contour plots of CXCR5+PD-1+++ of total
CD4+CD3+CD45RA− cells 7 d after the third P27A vaccina-
tion. Alum group, n = 7; GLA-SE group, n = 8. (E) Fold change
of CXCR5+PD-1+++ cTfh cells 7 d after the third P27A vac-
cination (frequency of cTfh cells at day 63/baseline). Alum
group, n = 7; GLA-SE group, n = 8. P = 0.0024. The P value is
from an unpaired Student’s t test. (F) Correlation of the
increase in anti-P27A IgG antibody titer 238 d after the first
vaccination (relative to baseline) against the fold change in
CXCR5+PD-1+++ cTfh cells 7 d after the third vaccination
(day 63); n = 15. Rho = 0.7; P = 0.005 using Spearman’s
correlation. Each symbol represents one individual; those
who received Alum are shown in black, and those who re-
ceived GLA-SE are in white. Data are from one clinical trial.
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Bentebibel et al., 2011; Lee et al., 2011). Here, we describe that a
similar compartmentalization can be applied to the circulating
counterparts of Tfh cells. The ICOS+CD38+CXCR5+PD-1+ cTfh
cells represent a larger group of B cell helper cells; within this
cTfh population, those cells with the highest expression of PD-
1 are the most similar to the GC-Tfh cells found in human LNs,
consistent with previous work (Heit et al., 2017). Analysis of the
transcriptome of cTfh cells has the potential to yield information
about how vaccination changes the phenotype of Tfh cells. We
observed changes in the transcriptome of these cells 7 d after
seasonal subunit influenza vaccination in UK adults. These in-
cluded alterations in the expression of CXCR3 and CCR6, che-
mokine receptors known to be affected by this vaccination
(Bentebibel et al., 2013), demonstrating that RNA sequencing is a
viable approach to detect phenotypic changes in cTfh cells after
vaccination. However, our study did not detect differences in the
transcriptomes of ICOS+CD38+CXCR5+PD-1+ cTfh cells 7 d after
the third inoculation with a synthetic peptide formulated in
Alum and GLA-SE, suggesting that the main difference in cTfh
cells driven by these adjuvants is quantitative rather than
qualitative. This quantitative difference may arise from the
distinct mechanisms of action of the two adjuvants; while GLA-
SE is thought to exert its effect on subcapsular sinus macro-
phages via IL-18 and TLR4 (Desbien et al., 2016), Alum does not
act through TLRs but instead may act via the inflammasome
(Eisenbarth et al., 2008). The stable emulsion (SE) in GLA-SE
has adjuvant properties on its own, such as is seen for emulsion
adjuvants like MF59. It is clear from preclinical studies that the
combination of GLA with SE creates a more potent stimulator of
both humoral immunity and the Tfh cell response than either
component individually (Desbien et al., 2016; Knudsen et al.,
2016). Therefore, it is likely that this combination adjuvant is
responsible for supporting the enhanced cellular immune re-
sponse described in this study. Our results indicate that, despite
different mechanisms of innate immune cell activation by these
two adjuvants, they do not affect innate immune cells in a way
that results in a qualitatively different Tfh cell response.
Our transcriptomic analysis revealed that GLA-SE also
promotes the emergence of common TCRβ clonotypes in cTfh
cells that were shared between five of eight individuals. The
emergence of so-called public clonotypes is informative for
vaccine design as it indicates that there may be a common,
immune-dominant epitope that could be used to specifically
enhance T cell responses in human populations. The recent
discoveries of public antibody clonotypes have revolutionized
whole-parasite malaria vaccine strategies (Imkeller et al.,
2018; Tan et al., 2018), and here, we extend this to the iden-
tification of public cTfh cell TCRβ clonotypes induced after
vaccination. The identification of these common TCRβ clo-
notypes in cTfh cells from participants who received the GLA-
SE–formulated vaccine could be a consequence of the greater
magnitude of the response, indicating that more T cell clones
are recruited into the cTfh cell response. The knowledge of
key antigenic peptides to which multiple individuals respond,
combined with adjuvants that allow a better recruitment of
Tfh cells into the GC, outlines a rational way to enhance
vaccine responses at the population level.
To date, there have been multiple subtypes of cTfh cells
identified that have different activation states and functional
capacities (Morita et al., 2011; Bentebibel et al., 2013; Locci et al.,
2013; Schmitt et al., 2014). Here, we aimed to identify the pop-
ulation of cTfh cells that are most similar to GC-Tfh cells in
human LNs. While GC-Tfh cells are likely to be the most infor-
mative cell type in vaccination trials in which the generation of
long-lived somatically mutated GC-derived ASCs is desirable,
obtaining GC-Tfh cells is not possible in large vaccination
studies. We show here that cTfh can provide surrogacy for GC-
Tfh cells, including insights into the transcriptome of Tfh cells.
CXCR5+PD-1+++ cTfh cells have a similar, although not identical,
RNA profile to GC-Tfh cells found in LNs. These two cell types
also shared TCRβ clonotypes, which indicates they may be
clones derived from the same cell. This clonal relationship is
consistent with a previous study (Heit et al., 2017), which to-
gether with the data presented here suggests that cTfh cells with
high PD-1 expression are closely clonally and transcriptionally
related to GC-Tfh cells. This study supports the relevance of
studying the CXCR5+PD-1+++ cTfh population in this and future
studies of how vaccines shape human GC-Tfh cell biology. Our
finding that GLA-SE can enhance the GC-Tfh-like cTfh popula-
tion and long-lived antibody response in the P27A vaccine trial
demonstrates that the adjuvant should be a key consideration in
vaccine design to maximize the generation of protective T cell–
dependent humoral immunity in humans.
Materials and methods
Study design
Themain research objective of this studywas to characterize the
cTfh cell and ASC responses to vaccination in humans at the
cellular and molecular level. To that end, two related studies
were performed: (1) peripheral blood was tested from 41 healthy
UK adults (18–98 yr of age) who were vaccinated with the tri-
valent influenza vaccine (northern hemisphere winter
2016–2017) and (2) 16 healthy HIV-negative Tanzanian male
adults (18–45 yr old) withminimal malaria exposure (urban Dar-
es-Salaam), who were vaccinated with 50 µg P27A peptide for-
mulated in either Alhydrogel (n = 8) or 5 µg GLA-SE (n = 8).
Serum was available for all participants for analysis, and pe-
ripheral blood mononuclear cells (PBMCs) were available from
seven in the Alhydrogel-vaccinated group and eight in the GLA-
SE–vaccinated group (Steiner-Monard et al., 2019). Circulating
Tfh cells and ASCs were identified by flow cytometry in samples
before and after vaccination and were flow-sorted for mRNA or
B cell receptor (BCR) repertoire sequencing, respectively. Re-
searchers remained blinded to the adjuvant group throughout
sample processing and data acquisition. Tonsil samples were
collected from adults undergoing routine tonsillectomy at
Cambridge University Hospitals NHS Foundation Trust. Paired
blood and LN samples were taken from patients recruited from
the renal transplant live donor program at Cambridge Univer-
sity Hospitals NHS Foundation Trust and who provided in-
formed consent. All patients were either receiving or within 6
mo of requiring renal replacement therapy. Patients taking
immunosuppressive medication before the transplant were
Hill et al. Journal of Experimental Medicine 12
The adjuvant GLA-SE enhances human Tfh responses https://doi.org/10.1084/jem.20190301
excluded. 50 ml of blood was taken at the time of transplant,
before knife to skin. Lymphoid tissue was removed as part of the
routine operative procedure as previously described (Wallin
et al., 2014). All human blood and tissue were collected in ac-
cordance with the latest revision of the Declaration of Helsinki
and the Guidelines for Good Clinical Practice. The seasonal UK
influenza vaccination cohort was collected with UK local re-
search ethics committee (REC) approval (REC reference 14/SC/
1077), using the facilities of the Cambridge Bioresource (REC
reference 04/Q0108/44). The P27A vaccine phase Ib trial
(ClinicalTrials.gov Identifier: NCT01949909, Pan African Clini-
cal Trial Registry identifier: PACTR201310000683408) was
conducted with approval from the Tanzanian Food and Drug
Administration (TFDA; Dar-es-Salaam, TFDA13/CTR/004/03),
National Institute for Medical Research (NIMR; Dar-es-Salaam,
NIMR/HQ/R8a/Vol.IX/1742), Swiss Agency for Therapeutic
Products (Swissmedic, Bern, Switzerland, reference no.
2013DR1165), and ethical review boards at Ifakara Health Insti-
tute and the University of Lausanne. Use of P27A trial samples in
the UKwas approved by the UK Health Research Authority (REC
reference 17/EE/0063) and Babraham Institute Human Ethics
Committee. Tonsil tissues and paired blood and LN samples
were collected from UK adults undergoing surgery for their own
medical care, under ethical approval from UK Health Research
Authority (REC references 16/LO/0453 and 11/EE/0355, respec-
tively) at Cambridge University Hospitals and processed at the
Babraham Institute. Written informed consent was received
from all volunteers.
Cell isolation of PBMC, LN, and tonsillar lymphocytes
Blood samples were collected into EDTA-coated tubes on the day
of vaccination (before administration of the vaccine) and at the
indicated time points. PBMCs were isolated using 15 ml
Histopaque-1077 (Sigma-Aldrich) then frozen in fetal bovine
serum supplemented with 10% dimethyl sulfoxide (Sigma-
Aldrich) overnight in a methanol bath at −80°C, then kept in
liquid nitrogen before analysis by flow cytometry. To isolate a
single cell suspension from secondary lymphoid tissues, tonsil
and LN samples were finely minced and then pressed through
a 70-µm cell strainer (Becton Dickinson), cells were washed
twice in 50 ml sterile PBS, then frozen as above.
Flow cytometry and sequencing of cTfh cells, tissue Tfh cells,
and ASCs
Cryopreservedmononuclear cells were thawed and rested for 1 h
at 37°C. Cell types were pre-enriched using MagniSort CD19
Positive Selection followed by CD4 memory T cell enrichment
(eBioscience). Fc receptors on all cells were blocked using hu-
man IgG, followed by staining with panels outlined in Table 1
and separation on BD Biosciences Aria Fusion or Influx cell
sorters. A dump channel consisting of viability dye and anti-
bodies to CD14, CD16, and either CD19 or CD3 was used to ex-
clude unwanted cell types from cTfh cell and ASC sorts,
respectively. HA-specific CD4+ T cells were identified using class
II tetramers with methods and reagents that have been previ-
ously reported (Yang et al., 2013). Gating strategies for
ICOS+CD38+PD-1+CXCR5+ cTfh cells and ASCs are included as
Fig. S5. Tonsil and LN cells were stained with the same flow
cytometry panel as cTfh cells, and ∼4 million cells were cos-
tained for intracellular Bcl6 (Clone K112-91) after permeabiliza-
tion with the transcription factor fixation/permeabilization kit
(Life Technologies). mRNA was isolated from sorted cTfh
cells (CD4+CD45RA−CXCR5+PD1+ICOS+CD38+ cells) using the
SMART-Seq V4 Ultra-Low Input RNA kit (Takara Bio) and
sorting 200 cells directly into lysis buffer. mRNA from paired
blood and LN CD4+CD45RA− T cell populations was isolated
from 52–1,000 cells sorted into lysis buffer. cDNA libraries
were subsequently generated using the Nextera XT DNA Li-
brary Prep Kit (Illumina), followed by sequencing on the Illu-
mina HiSeq 2000 with ∼50 million 100-bp single-end reads per
sample. ASCs (CD19+IgD−CD27+CD71+CD20−CD38+) were sorted
into RNAlater (500–10,000 cells) and RNA isolated using the
RNeasy Micro kit (Qiagen). In all samples for which sufficient
RNA was extracted, immunoglobulin heavy (IgG, IgM) chains
were amplified using 59RACE with unique molecular identifiers
as previously reported (Turchaninova et al., 2016; Davydov
et al., 2018) using Q5 High-Fidelity DNA Polymerase (New
England BioLabs) and sequencing on the Illumina MiSeq (340 ×
280-bp paired-end).
Serology
IgG to influenza HA proteins were measured before and after
vaccination by Luminex using magnetic beads coated with full-
length recombinant HA proteins from A/California/07/2009
(Cali09) and B/Brisbane/60/2008 (Bris08) as previously re-
ported (Wang et al., 2015). IgG to P27A was measured by ELISA
as previously reported (Steiner-Monard et al., 2019). Titers are
represented as arbitrary units per milliliter, and where indi-
cated, preexisting IgG titers were subtracted to calculate
vaccination-induced IgG responses.
Differential gene expression analysis
Transcriptomic analyses of cTfh cells and LN Tfh cell pop-
ulations were performed using the SeqMonk software package
(Babraham Institute, https://www.bioinformatics.babraham.ac.
uk/projects/seqmonk/) after alignment of reads to the reference
human genome GRCh38 using HISAT2 (Kim et al., 2015). Reads
were quantitated over exons, the library size was standardized
to 1 million reads, and then read counts were log2 transformed.
Differentially expressed genes were determined by DESeq2 us-
ing raw counts (adjusted P value cutoff, <0.05; Love et al., 2014).
Hierarchical clustering and PC analysis were performed using
variable genes (those with a standard deviation of >0.7 when
comparing all the datasets). The LN GC-Tfh signature was gen-
erated using DESeq2 and applying a post hoc z-score threshold of
0.9 to select the genes most highly or least expressed in GC-Tfh
cells relative to other LN populations.
TCRβ clonotyping and V(D)J sequencing
TCRβ clonotypes were called from adaptor-trimmed RNA se-
quencing fastq files using MIXCR (version 2.1.9; Bolotin et al.,
2015) run in RNA-Seqmode (mixcr align -p rna-seq -c TRB -s hsa
-OallowPartialAlignments = true) with rescuing of partial
alignments and set to collate clonotypes at the amino acid level
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rather than the nucleotide level and requiring more than five
reads to identify a clonotype. Clonotype diversity and sharing
were determined using vdjtools (version 1.0.3; Shugay et al.,
2015). Processing and analysis of the V(D)J sequencing reads of
ASCs were done using MIGEC and MiXCR as described in
Turchaninova et al. (2016) but with some changes. Briefly,
“migec Histogram” was used as described but with omitting the
“--only-first-read” command. The recommended molecular
identifier group (MIG)–size thresholding from this was used to
select MIGs with sufficient over-sequencing to allow efficient
error correction in the subsequent “migec Assemblebatch”
process and “--only-first-read” was again omitted from “migec
Assemblebatch.” Over-sequencing thresholds used ranged from
3–16 with the majority (27 of 30) being ≥4. The “kaligner”
alignment algorithm was used in “mixcr align” to map reads to
the “VTranscipt” feature as recommended for full-length V(D)J
data. Vdjtools (version 1.1.7; Shugay et al., 2015) was used for
summarizing and visualizing results. SHM was analyzed using
IMGT HighV-QUEST (Brochet et al., 2008). Briefly, full-length
(FR1–FR4) V region nucleotide sequences of clonotypes output
byMiXCR were filtered to remove noncoding, incomplete (these
were both always very-low-frequency clonotypes) and non-IgG
clonotypes. The sequences of the remaining coding, complete
IgG clonotypes were submitted to IMGT HighV-QUEST and
SHM analyzed using the “V-REGION-nt-mutation-statistics”
output file. CDR3 was omitted from this since SHM of this
cannot be differentiated from changes that occurred during
V(D)J recombination and SHM of FR4 is not analyzed by IMGT.
Clonotype sizes and SHM frequencies were analyzed and visu-
alized using Excel and Graphpad prism.
Data availability
RNA-sequencing data of cTfh before and 7 d after influenza vac-
cination in the UK cohort presented in Fig. 1 are available from
Array Express (accession no. E-MTAB-7955). RNA-sequencing
data cTfh before and 7 and 28 d after P27A vaccination from the
Clinical Trial presented in Figs. 3 and 4 are available from the Gene
Expression Omnibus (GEO; accession no. GSE131088). V(D)J-
sequencing data from ASCs before and 7 and 28 d after P27A
vaccination from the clinical trial presented in Fig. 5 are avail-
able from GEO (accession no. GSE131090). RNA-sequencing data
presented in Fig. 6 from different CD45RA−CD4+CD3+ T cell
populations isolated from paired blood and LN samples are
available from GEO (accession no. GSE131089).
Statistical analyses
Shapiro-Wilk testing indicated that the cTfh cell frequencies
follow a normal distribution in both the UK influenza
Table 1. Antibodies used for flow cytometry
Marker Clone Fluorochrome Company Catalog no.
Viability dye n/a eFluor780 eBioscience 65-0865-14
CD14 61D3 APC-eF780 eBioscience 47-0149-42
CD16 eBioCB16 APC-eF780 eBioscience 47-0168-42
CD3 UCHT1 APC-eF780 eBioscience 47-0038-42
CD19 HIB19 BB515 BD Biosciences 564456
CD20 2H7 PECY7 BioLegend 302312
CD71 CY1G4 PE BioLegend 334106
IgD IA6-2 BV421 BD Biosciences 563813
CD27 M-T271 BV510 BioLegend 356420
CD38 HIT2 APC eBioscience 17-0389-42
CD19 HIB19 APC-eF780 eBioscience 47-0199-42
ICOS ISA-3 APC eBioscience 17-9948-42
CD3 UCHT1 BUV 395 BD Biosciences 563546
CD45RA HI100 BUV737 BD Biosciences 564442
CXCR5 RF8B2 BB515 BD Biosciences 564624
CD4 RPA-T4 PercpCy5.5 BD Biosciences 560650
PD1 eBioJ105 PECy7 eBioscience 25-2799-42
CD38 HIT2 BV421 BioLegend 303525
CD127 A019D5 BV650 BioLegend 351325
BCL6 K112-91 PE BD Biosciences 561522
CXCR3 1C6/CXCR3 BV421 BD Biosciences 562558
CCR6 11A9 BV786 BD Biosciences 563704
n/a, not applicable.
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vaccination cohort and Tanzanian P27A vaccination cohort. For
the UK influenza vaccination studies, comparisons were made
between days 0 and 7 for each individual with a paired Student’s
t test. For the P27A study, comparisons between the Alum and
GLA-SE groups were done using a two-tailed unpaired Student’s
t test. ASC frequencies and serum IgG levels in the Tanzanian
P27A vaccination cohort did not follow a normal distribution and
were analyzed using aMann-Whitney U test. Comparisons of the
IgG titer from multiple time points in the Tanzanian P27A vac-
cination cohort were calculated on log-transformed data using a
two-way ANOVA with Sidak’s multiple-comparisons test. The
Kruskal-Willis test was used to compare TCRβ sharing in the
paired blood and LN study. The number of cells sorted per
population and the number of TCRβ clonotypes for the paired
blood and LN study are shown in Table 2. Figure legends include
the test and the number of observations.
For paired blood and LN analysis of TCRβ clonotyping, we
used the following strategy to allow for the effect of the smaller
cell numbers in blood “population 4” (ICOS+CD38+CXCR5+PD-1+)
based upon a prior study (Shugay et al., 2013). This paper shows
for 12 unrelated donor pairs that the number of shared clono-
types (Y) is directly proportional to the square of the number of
clonotypes tested (X), such that Y = aX2, where a is a constant.
This extends work from Robins et al. (2010), which used a
similar power law to extrapolate TCRβ clonotyping to estimate
the total size of the human naive CD8 pool. We, therefore,
normalized our observed sharing frequencies between pop-
ulations i and j (Yij) as follows.
Normalized sharing count between populations i and j, Nor-
mYij = Yij/((Xi + Xj)/2)2 where Xi and Xj are the number of clo-
notypes identified in populations i and j, respectively. For some
comparisons, Yijwas equal to 0. To allow normalization, we used
pseudocounts (ψYij = Yij + 0.01):
NormψYij  (Yij + 0.01)
.
Xi + Xj

2
2
.
We calculated NormψY between all eight populations (8!/2!6! =
28 comparisons) for each individual.
Online supplemental material
Fig. S1 shows the expression of CD38 and ICOS on tonsillar Tfh
cells and the relationship of CD38+ICOS+CXCR5+PD-1+ Tfh cells
with GC B cells. Fig. S2 shows HA-specific CD4+ T cells within
the cTfh cell population 7 d after vaccination. Fig. S3 shows the
proportion of the 40 most abundant TCRβ CDR3 clonotypes in
ICOS+CD38+CXCR5+PD-1+ cTfh cells from each P27A study par-
ticipant. Fig. S4 compares the frequency of ASCs before vacci-
nation in both the UK and Tanzanian cohorts. Fig. S4 also
shows the 100 most abundant BCR clonotypes in the
CD382+CD20−CD19+ ASCs of individual P27A study participants.
Fig. S5 shows the gating strategy for fluorescence-activated cell
sorting of cTfh cells and ASCs.
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